Effect of tamsulosin therapy on lower urinary tract symptoms in Parkinson's disease

Basit Öğe Kaydı
dc.authorscopusid56580135300
dc.authorscopusid8944423300
dc.authorscopusid17135509300
dc.authorscopusid24335118600
dc.authorscopusid8944423400
dc.authorscopusid14066287100
dc.contributor.authorGörür, Sadik
dc.contributor.authorMelek, Ismet Murat
dc.contributor.authorOkuyucu, Esra
dc.contributor.authorHelli, Ali
dc.contributor.authorDuman, Taşkin
dc.contributor.authorKiper, Ahmet Namik
dc.date.accessioned2024-09-19T15:45:21Z
dc.date.available2024-09-19T15:45:21Z
dc.date.issued2008
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractIntroduction: The aim of this study is to evaluate the intensity of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) with and without Parkinson's disease (PD). We also investigated the efficacy of tamsulosin therapy in the management of the subjective and objective symptoms in these patients. Materials and Methods: This study included 80 (40 patients with and 40 without PD) clinically diagnosed BPH patients treated with tamsulosin. International Prostate Symptom score (IPSS), quality of life (QoL), maximum flow rate (Qmax) and post-void residual urine volume (PVR) were determined at baseline and after the 3 months of therapy. The PD group also evaluated with Unified Parkinson's Disease Rating Scale (UPDRS). All patients had received tamsulosin 0.4 mg/per day for 3 months period. The relationship between PD duration and UPDRS and mean changes of IPSS, QoL, Qmax and PVR after tamsulosin therapy were also investigated in PD group. Results: Three patients (7.5%) in PD group were discontinuied the therapy due to the severe hypotension attack. Initial data of IPSS, QoL, Qmax and PVR were different between two groups (p<0.001). After tamsulosin treatment, LUTS improved significantly in both groups (p<0.05). Improvement rates of the IPSS, QoL, Qmax and PVR were significantly higher in non-PD group (p<0.05). When relationship were investigated between PD duration and UPDRS and mean changes of IPSS, QoL, Qmax and PVR after tamsulosin therapy, all parameters were found in correlation except PVR. Conclusion: Tamsulosin therapy appears to useful in PD patient with BPH. But its efficacy is changed with PD duration and severity. After all, tamsulosin therapy can be given to these patients group with close follow-up.en_US
dc.identifier.endpage117en_US
dc.identifier.issn1300-5804
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-44449146403en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage113en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14605
dc.identifier.volume34en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofTurk Uroloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBPHen_US
dc.subjectLower Urinary Tract Symptomsen_US
dc.subjectParkinson's Diseaseen_US
dc.subjectTamsulosinen_US
dc.titleEffect of tamsulosin therapy on lower urinary tract symptoms in Parkinson's diseaseen_US
dc.title.alternativeParkinson hastalarinda tamsulosin tedavisinin alt üriner sistem belirtileri üzerine etkisien_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
277 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu